Get the Stockscreener App
1.69
0.59%
-0.01
After Hours:
1.69
Proqr Therapeutics N V stock is traded at $1.69, with a volume of 319.89K.
It is down -0.59% in the last 24 hours and up +15.75% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$1.70
Open:
$1.7
24h Volume:
319.89K
Relative Volume:
0.66
Market Cap:
$178.03M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-4.4615
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
+6.29%
1M Performance:
+15.75%
6M Performance:
-31.02%
1Y Performance:
-17.16%
1-Day Range:
$1.64
$1.71
1-Week Range:
$1.49
$1.71
52-Week Range:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.69 | 179.09M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday - Defense World
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference - 富途牛牛
Surprises Report: Is ProQR Therapeutics NV a potential multi baggerWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
PRQR Should I Buy - Intellectia AI
Retail Trends: Is ProQR Therapeutics NV a potential multi baggerJuly 2025 Momentum & Risk Managed Investment Signals - baoquankhu1.vn
Aberdeen Group plc Grows Position in ProQR Therapeutics N.V. $PRQR - Defense World
Can ProQR Therapeutics N.V. weather a recession2025 Fundamental Recap & Low Drawdown Momentum Ideas - mfd.ru
ProQR Therapeutics (PRQR) Leadership to Discuss Company Developm - GuruFocus
Aug Shorts: Is ProQR Therapeutics NV stock a buy or sellProfit Target & High Return Stock Watch Alerts - baoquankhu1.vn
How interest rate cuts could boost ProQR Therapeutics N.V. stockProfit Target & Real-Time Buy Signal Notifications - mfd.ru
What’s the RSI of ProQR Therapeutics N.V. stock2025 Big Picture & Community Verified Trade Alerts - mfd.ru
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January - MarketBeat
Can ProQR Therapeutics N.V. withstand a market correctionCPI Data & Community Verified Watchlist Alerts - mfd.ru
Is ProQR Therapeutics N.V. currently under institutional pressureChart Signals & Long-Term Growth Portfolio Plans - mfd.ru
PRQR PE Ratio & Valuation, Is PRQR Overvalued - Intellectia AI
Will ProQR Therapeutics N.V. stock recover after earningsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
A | Is ProQR Therapeutics N.V. stock showing strong momentumJuly 2025 Levels & Risk Controlled Swing Alerts - mfd.ru
Aug Levels: Is ProQR Therapeutics NV stock a buy or sellJuly 2025 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ProQR announces board changes as two members set to depart By Investing.com - Investing.com Canada
ProQR announces board changes as two members set to depart - Investing.com
ProQR Therapeutics (PRQR) Announces Board Changes at Upcoming AG - GuruFocus
ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM - TipRanks
Myriad Genetics (NASDAQ:MYGN) & ProQR Therapeutics (NASDAQ:PRQR) Head-To-Head Survey - Defense World
ProQR Aktie: Pipeline-Fortschritte - Börse Global
Risk Recap: Will ProQR Therapeutics NV stock recover after earningsJuly 2025 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Dip Buying: Is Sharps Technology Inc Equity Warrant in a bullish channelWeekly Market Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Recap: Is ProQR Therapeutics NV a cyclical or defensive stockEarnings Trend Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Quarterly Earnings: Can ProQR Therapeutics NV weather a recessionWeekly Stock Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 28% - 富途牛牛
Aug PreEarnings: Is KFFB stock undervalued right nowTrade Entry Report & Weekly Stock Performance Updates - baoquankhu1.vn
Market Recap: Can SBEV be recession proofQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Earnings Miss: Can ProQR Therapeutics NV reach resistance levels soon2025 AllTime Highs & Expert Verified Movement Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Day Trade: Does OLMA have strong EBITDA marginsJuly 2025 Volume & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Published on: 2026-01-18 21:01:57 - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aug Patterns: What insider trading reveals about ProQR Therapeutics NV stockProfit Target & Consistent Growth Equity Picks - Bộ Nội Vụ
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st
Working capital per share of ProQR Therapeutics N.V. – FWB:0PQ - TradingView — Track All Markets
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com Nigeria
Will ProQR Therapeutics N.V. stock deliver long term returnsDip Buying & Free Community Consensus Stock Picks - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - Улправда
ProQR stock falls after initial AX-0810 data, pipeline updates - Investing.com
ProQR announces encouraging AX-0810 phase 1 - MarketScreener
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):